SBI Okasan Asset Management Co.Ltd. Invests $522,000 in NewAmsterdam Pharma Company N.V. $NAMS

SBI Okasan Asset Management Co.Ltd. purchased a new stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,900 shares of the company’s stock, valued at approximately $522,000.

Several other large investors have also made changes to their positions in the company. Capital World Investors lifted its stake in shares of NewAmsterdam Pharma by 17.1% during the third quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after acquiring an additional 1,434,986 shares during the period. Wellington Management Group LLP lifted its stake in shares of NewAmsterdam Pharma by 21.0% during the third quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after acquiring an additional 697,129 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in shares of NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after acquiring an additional 1,062,359 shares during the period. Polar Capital Holdings Plc lifted its stake in shares of NewAmsterdam Pharma by 15.6% during the third quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock valued at $82,807,000 after acquiring an additional 393,855 shares during the period. Finally, Alliancebernstein L.P. lifted its stake in shares of NewAmsterdam Pharma by 4.0% during the second quarter. Alliancebernstein L.P. now owns 2,331,583 shares of the company’s stock valued at $42,225,000 after acquiring an additional 89,630 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Trading Down 4.9%

NASDAQ:NAMS opened at $33.68 on Friday. The firm has a market capitalization of $3.94 billion, a price-to-earnings ratio of -18.82 and a beta of 0.02. The business’s 50-day moving average price is $33.34 and its two-hundred day moving average price is $34.20. NewAmsterdam Pharma Company N.V. has a 1-year low of $16.95 and a 1-year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The business had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. Sell-side analysts predict that NewAmsterdam Pharma Company N.V. will post -1.76 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on NAMS. Truist Financial began coverage on NewAmsterdam Pharma in a research note on Wednesday, March 18th. They set a “buy” rating and a $57.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Needham & Company LLC upped their price target on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Finally, Guggenheim upped their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $48.00.

Insiders Place Their Bets

In other news, Director Louis G. Lange sold 44,619 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $30.42, for a total transaction of $1,357,309.98. Following the sale, the director owned 10,360 shares of the company’s stock, valued at $315,151.20. This trade represents a 81.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael H. Davidson sold 443,707 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $33.25, for a total value of $14,753,257.75. Following the sale, the chief executive officer directly owned 174,144 shares in the company, valued at approximately $5,790,288. This represents a 71.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 881,512 shares of company stock worth $28,350,236. 12.74% of the stock is owned by company insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.